The Prognostic Value of the Expression of Programmed Death Ligand 1 (PD-L1) in Early Stage Non-small-cell Lung Cancer
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 350
- 主要终点
- Expression
研究概览
简要总结
This is an observational retrospective study. The primary objective is to investigate the expression and potential prognostic role of Programmed Death Ligand 1 (PD-L1) in tumor samples from 350 patients with early stage treatment-naive non-small-cell lung cancer (NSCLC).
Tissue samples were embedded in a tissue microarray. PD-L1 will be studied by immunohistochemistry using the SP263 antibody. Stained samples will be evaluated independently by two operators. A tumor will be defined as positive when = or >50% of tumor cells express the ligand.
The investigators will investigate the relationship between PD-L1 protein expression and overall survival and other clinical characteristics with appropriate statistical methods.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Early stage treatment-naive NSCLC
排除标准
- •Received any pre-surgical treatment
- •no OS data available
结局指标
主要结局
Expression
时间窗: 15 days
The study will investigate PD-L1 protein expression by immunohistochemistry in tumor samples from early stage NSCLC
Prognostic value
时间窗: 15 days
The correlation between PD-L1 protein expression by immunohistochemistry and overall survival will be studied
次要结局
未报告次要终点